Sign In
Buy TRUMF
Terumo Earnings Calls
| Release date | May 15, 2026 |
| EPS estimate | $0.0945 |
| EPS actual | $0.113 |
| EPS Surprise | 19.04% |
| Revenue estimate | 1.827B |
| Revenue actual | 1.891B |
| Revenue Surprise | 3.51% |
| Release date | Feb 13, 2026 |
| EPS estimate | $0.144 |
| EPS actual | $0.141 |
| EPS Surprise | -1.87% |
| Revenue estimate | 1.83B |
| Revenue actual | 1.893B |
| Revenue Surprise | 3.40% |
| Release date | Nov 12, 2025 |
| EPS estimate | $0.166 |
| EPS actual | $0.161 |
| EPS Surprise | -3.02% |
| Revenue estimate | 1.79B |
| Revenue actual | 1.859B |
| Revenue Surprise | 3.83% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.169 |
| EPS actual | $0.196 |
| EPS Surprise | 15.65% |
| Revenue estimate | 1.793B |
| Revenue actual | 1.795B |
| Revenue Surprise | 0.140% |
Last 4 Quarters for Terumo
Below you can see how TRUMF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $17.90 |
| EPS estimate | $0.169 |
| EPS actual | $0.196 |
| EPS surprise | 15.65% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $17.90 |
| Aug 01, 2025 | $17.90 |
| Aug 04, 2025 | $17.90 |
| Aug 05, 2025 | $17.90 |
| Aug 06, 2025 | $17.90 |
| Aug 07, 2025 | $18.10 |
| Aug 08, 2025 | $16.75 |
| Aug 11, 2025 | $16.73 |
| Aug 12, 2025 | $18.71 |
| 4 days before | 0% |
| 4 days after | 4.53% |
| On release day | 1.12% |
| Change in period | 4.53% |
| Release date | Nov 12, 2025 |
| Price on release | $15.29 |
| EPS estimate | $0.166 |
| EPS actual | $0.161 |
| EPS surprise | -3.02% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $16.20 |
| Nov 07, 2025 | $15.04 |
| Nov 10, 2025 | $17.59 |
| Nov 11, 2025 | $15.10 |
| Nov 12, 2025 | $15.29 |
| Nov 13, 2025 | $16.54 |
| Nov 14, 2025 | $16.60 |
| Nov 17, 2025 | $15.08 |
| Nov 18, 2025 | $14.62 |
| 4 days before | -5.59% |
| 4 days after | -4.43% |
| On release day | 8.12% |
| Change in period | -9.78% |
| Release date | Feb 13, 2026 |
| Price on release | $13.91 |
| EPS estimate | $0.144 |
| EPS actual | $0.141 |
| EPS surprise | -1.87% |
| Date | Price |
|---|---|
| Feb 09, 2026 | $13.30 |
| Feb 10, 2026 | $13.74 |
| Feb 11, 2026 | $13.74 |
| Feb 12, 2026 | $13.27 |
| Feb 13, 2026 | $13.91 |
| Feb 17, 2026 | $12.52 |
| Feb 18, 2026 | $12.69 |
| Feb 19, 2026 | $12.52 |
| Feb 20, 2026 | $12.52 |
| 4 days before | 4.59% |
| 4 days after | -9.96% |
| On release day | -9.99% |
| Change in period | -5.83% |
| Release date | May 15, 2026 |
| Price on release | $11.60 |
| EPS estimate | $0.0945 |
| EPS actual | $0.113 |
| EPS surprise | 19.04% |
| Date | Price |
|---|---|
| May 11, 2026 | $11.49 |
| May 12, 2026 | $11.60 |
| May 13, 2026 | $11.60 |
| May 14, 2026 | $11.60 |
| May 15, 2026 | $11.60 |
| May 18, 2026 | $11.60 |
| May 19, 2026 | $11.60 |
| May 20, 2026 | $11.60 |
| May 21, 2026 | $11.60 |
| 4 days before | 0.92% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0.92% |
Terumo Earnings Call Transcript Summary of Q1 2026
Terumo reported a strong FY'25 Q1 with record quarterly revenue of JPY 260 billion and record adjusted operating profit (JPY 55.9 billion). Revenue rose ~6% ex-FX, driven by the Americas (especially TIS) and growth in China (neuro via VBP). Profit expansion outpaced revenue thanks to pricing actions, productivity/VC improvements, and cost control; Q1 free cash flow was JPY 10.5 billion (down YoY due to higher inventories and tariff-related stocking). Tariff impact to the full year has been revised down from JPY 17.5 billion to roughly JPY 10 billion (most to materialize in H2), and management intends to mitigate tariffs through price pass-through where feasible. Segment highlights: Cardiovascular saw margin improvement (29% operating margin) from pricing and profitability initiatives; TMCS faced temporary declines from divestitures and supply timing; TBCT (Global Blood Solutions) benefited from plasma innovation (Rika) deployments and improving production efficiency. Management kept full-year guidance unchanged, citing Q1 upside (pricing and volume) that offsets expected tariff headwinds.
